Source comparison
MK-677 for Andropause Research: Product Comparison
MK-677 (ibutamoren) Ghrelin receptor agonist. Stimulates endogenous GH pulses Once daily (oral) None. Preserves testosterone and LH/FSH Andropause lean mass retention, sleep quality, IGF-1 restoration in elderly Best choice for andropause research focused on G
This comparison does not assign a generated winner or score.
- MK-677 (ibutamoren)
- Ghrelin receptor agonist. Stimulates endogenous GH pulses
- Once daily (oral)
- None. Preserves testosterone and LH/FSH
- Andropause lean mass retention, sleep quality, IGF-1 restoration in elderly
- Best choice for andropause research focused on GH axis without testosterone interference; requires glucose monitoring in metabolically compromised subjects
- Exogenous GH (somatropin)
- Direct GH replacement
- Daily injection
- Yes. Suppresses endogenous GH production
- Severe GH deficiency, wasting syndromes
- Superior IGF-1 elevation but suppresses natural GH pulsatility; not suitable for research aiming to preserve endogenous hormone production
- CJC-1295 + Ipamorelin
- GHRH analog + ghrelin mimetic peptide combination
- 3–5x weekly (injection)
- Minimal. Mild LH suppression in some subjects
- Body recomposition research, recovery protocols
- More targeted GH release than MK-677 but requires injection and has shorter duration; often preferred in athletic research populations
- Sermorelin
- GHRH analog. Stimulates pituitary GH release
- None
- GH deficiency diagnosis and mild restoration
- Gentler GH elevation than MK-677 but less reliable IGF-1 response in elderly; primarily diagnostic rather than therapeutic in research contexts
- Testosterone replacement (enanthate, cypionate)
- Direct androgen replacement
- Weekly or biweekly injection
- Yes. Suppresses LH/FSH and endogenous testosterone
- Hypogonadism, andropause testosterone restoration
- Addresses testosterone axis only; does not restore GH/IGF-1; standard first-line for andropause but leaves GH decline unaddressed